Adage Capital Partners Gp, L.L.C. Annovis Bio, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.82 - $18.01 $723,000 - $2.7 Million	-150,000 Reduced 60.0%	100,000 $576,000
Q1 2024 May 15, 2024	SELL	$8.47 - $18.93 $299,389 - $669,118	-35,347 Reduced 12.39%	250,000 $2.98 Million
Q4 2023 Feb 14, 2024	SELL	$5.55 - $19.62 $81,324 - $287,491	-14,653 Reduced 4.88%	285,347 $5.34 Million
Q3 2023 Nov 14, 2023	BUY	$9.37 - $14.12 $2.81 Million - $4.24 Million	300,000 New	300,000 $2.85 Million

1.17M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $46.2M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.